Could Argentina give you bang for your buck?

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

High inflation, a drop in the price of its commodities and restrictions on imports have not made for a good economic environment in Argentina and have proved a turnoff for investors. But a general election is around the corner and there are hopes that a new administration may set things right. So with change blowing in the wind, companies with flagging pipelines should consider what Argentina has to offer, not least a rich R&D community that helped create the world's first ever cancer vaccine against non-small cell lung cancer, and a vibrant local industry open to partnerships .

High inflation, a drop in the price of its commodities and restrictions on imports have not made for a good economic environment in Argentina and have proved a turnoff for investors. But a general election is around the corner and there are hopes that a new administration may set things right. So with change blowing in the wind, companies with flagging pipelines should consider what Argentina has to offer, not least a rich R&D community that helped create the world's first ever cancer vaccine against non-small cell lung cancer, and a vibrant local industry open to partnerships .

Daniel Gomez, professor of the Quilmes University, and international affairs director at Chemo Labs, believes foreign firms – from small...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.